Yilai Shu, MD/PhD
Role
Target SAB member (not yet engaged). Asian-network anchor: clinical authority on cochlear gene therapy in mainland China, including the OTOF gene therapy trials at the Eye & ENT Hospital of Shanghai. Long collaborator with Jeffrey Holt.
Background
Director of the ENT Institute / Otorhinolaryngology Hospital, Fudan University. Led the first-in-human cochlear gene therapy trial in China for DFNB9/OTOF; published in The Lancet (2024). Bridges Western and Chinese clinical-trial ecosystems for inner-ear gene therapy.
Relationship history
- no contact yet — outreach to follow once Holt SAB letter signed (warm intro via Holt)
Active commitments
- Plan warm intro via Jeffrey Holt after SAB letter signed
- Draft SAB invitation letter tailored to Asia-bridge framing
Connections
[part-of]Board & Advisors[applies]index[see-also]Jeffrey Holt